CARM

0.00020.00%
SG

Saar Gill

Co-Founder & Chairman of Scientific Advisory Board

Dr. Saar Gill, M.D., Ph.D., is Co-Founder of CARISMA Therapeutics Inc. and serves as its Chairman of its Scientific Advisory Board since 2024. He serves as Assistant Professor of Hematology-Oncology in Penn's Abramson Cancer Center. He is Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, Attending Physician, Hematologic Malignancies at the University of Pennsylvania Health System and Member of the Abramson Cancer Center at the University of Pennsylvania. He obtained his medical degree from the University of Melbourne in Australia in 1999. He underwent internal medicine training at St Vincent's Hospital in Melbourne, followed by hematology training at the Peter MacCallum Cancer Centre and at the Royal Melbourne Hospital, which he completed in 2008. In 2008 he became a post-doctoral fellow at the laboratory of Robert Negrin at Stanford University, where he studied adoptive cellular therapy with NK cells. In 2011 Dr. Gill moved to the University of Pennsylvania where he did a Bone Marrow Transplant and Cellular Therapy fellowship under Dr. David Porter and started working in the laboratory with Dr. Michael Kalos on chimeric antigen receptor T cells for the treatment of acute myeloid leukemia (AML). The Gill Laboratory at the Center for Cellular Immunotherapies at the University of Pennsylvania was established in 2013 with the overarching goals to produce effective and safe CAR T cells for the treatment of hematologic malignancies such as leukemia and lymphoma. Current interests in the Gill Laboratory include the development of next generation gene editing approaches for adoptive cell therapy.

Positions